Patents by Inventor Robert Scott Pearsall

Robert Scott Pearsall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
    Patent number: 10227393
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: March 12, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • ALK4:ActRIIB heteromultimers and uses thereof
    Patent number: 10196434
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: February 5, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • Methods for treating refractory anemia with ringed sideroblasts
    Patent number: 10131700
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: November 20, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • METHODS FOR TREATING REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS
    Publication number: 20180312559
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: October 23, 2017
    Publication date: November 1, 2018
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Isolated nucleotide sequences encoding GDF traps
    Patent number: 9932379
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 3, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • METHODS FOR TREATING REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS
    Publication number: 20180037622
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: October 23, 2017
    Publication date: February 8, 2018
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS
    Publication number: 20170327800
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: July 28, 2017
    Publication date: November 16, 2017
    Applicants: Acceleron Pharma Inc., Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
  • ALK7 ANTAGONISTS AND USES THEREOF
    Publication number: 20170306027
    Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 26, 2017
    Inventors: John Knopf, Ravindra Kumar, Asya Grinberg, Robert Scott Pearsall, Dianne S. Sako, Roselyne Castonguay, Gang Li, Yossi Dagon
  • ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY
    Publication number: 20170240639
    Abstract: Disclosed herein are ActRII antagonists and methods for increasing immune responses and/or activity in patients in need thereof including, for example, cancer patients. In some embodiments, the disclosure relates to methods for treating cancer and/or tumors in a patient comprising administration of an ActRII antagonists and a PD1-PDL1 antagonist.
    Type: Application
    Filed: February 22, 2017
    Publication date: August 24, 2017
    Inventors: Ravindra Kumar, Marat Alimzhanov, Robert Scott Pearsall
  • ISOLATED GDF TRAP POLYPEPTIDE
    Publication number: 20170204382
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: October 27, 2016
    Publication date: July 20, 2017
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS
    Publication number: 20170137791
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: January 23, 2017
    Publication date: May 18, 2017
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
  • Use of GDF traps to treat anemia
    Patent number: 9505813
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: November 29, 2016
    Assignee: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • ISOLATED NUCLEOTIDE SEQUENCES ENCODING GDF TRAPS
    Publication number: 20160326228
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 10, 2016
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF
    Publication number: 20160298093
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.
    Type: Application
    Filed: April 6, 2016
    Publication date: October 13, 2016
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • ALK7:ACTRIIB HETEROMULTIMERS AND USES THEREOF
    Publication number: 20160297867
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
    Type: Application
    Filed: April 6, 2016
    Publication date: October 13, 2016
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay, Gang Li, Yossi Dagon
  • ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF
    Publication number: 20160289292
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
    Type: Application
    Filed: April 6, 2016
    Publication date: October 6, 2016
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
  • Isolated nucleotide sequences encoding GDF traps
    Patent number: 9439945
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: September 13, 2016
    Assignee: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • ISOLATED NUCLEOTIDE SEQUENCES ENCODING GDF TRAPS
    Publication number: 20140314759
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: March 7, 2014
    Publication date: October 23, 2014
    Applicant: ACCELERON PHARMA, INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Isolated nucleotide sequences encoding GDF traps
    Patent number: 8703927
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: April 22, 2014
    Assignee: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • ISOLATED GDF TRAP POLYPEPTIDE
    Publication number: 20130244324
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: January 25, 2013
    Publication date: September 19, 2013
    Applicant: ACCELERON PHARMA, INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar